In Situ Synthesis Of GPCR Ligands

描述(申请人提供)：G蛋白偶联受体(GPCRs)是人类基因组中最大的膜蛋白家族，约有800个成员。GPCR信号通过多个效应通路具有深远的治疗意义，使这些受体成为目前市场上40%药物的靶点。通过小分子配体调节gpr活性是抗癌治疗发展的一种新策略。然而，有限的结构信息阻碍了设计更高疗效和更低副作用的新药，以及对GPCR作用机制的详细了解。许多GPCRs的结构研究反过来又受到缺乏稳定GPCRs并使其结晶的高亲和力配体的限制。该项目试图利用原位点击化学方法开发一个新的平台，以发现与GPCRs结合的新配体，作为结构和功能研究的工具化合物或作为药物发现的起点。靶向合成方法包括原位点击化学，通过原位点击化学将反应片段连接到生物靶的结合部位，在药物发现方面显示出巨大的前景，但尚未应用于GPCRs。挑战在于GPCRs的膜配置、高构象动力学、低稳定性和低表达水平。拟议的平台正在开发中，目标是所有GPCR，最初的重点主要是那些已知的癌症靶点。在这两年的研究中，我们将重点关注平滑(SMO)受体，它是一种孤儿受体，也是Hedgehog(HH)信号通路中在发育过程中激活的关键信号转导，因此是许多抗肿瘤药物临床试验的靶点。我们的目标将通过以下两个目标来实现：(1)建立一个原位点击化学平台来生成高亲和力的GPCR配体；(2)通过结晶学表征从Aim 1中选择的配体与SMO之间的相互作用。这项研究将得到一个小组的支持，该小组开发了GPCR结构确定管道及其基本技术，自2007年以来，这些技术已经导致了12个GPCRs结构的确定。

DESCRIPTION (provided by applicant): G-protein coupled receptors (GPCRs) constitute the largest family of membrane proteins in the human genome with approximately 800 members. GPCR signaling through multiple effector pathways has profound therapeutic implications, making these receptors the targets of ~40% of currently marketed drugs. Modulation of GPCR activity by small molecule ligands is emerging as a new strategy for development of anticancer therapeutics. However, design of new drugs with higher efficacy and lower side effects, and detailed understanding of GPCR mechanism of action are hampered by the limited structural information. Structural studies of many GPCRs are in turn limited by a scarcity of high-affinity ligands that stabilize GPCRs and enable their crystallization. The project attempts to develop a new platform using the in situ click chemistry approach to discover novel ligands that bind GPCRs to serve as tool compounds for structural and functional studies or as starting point for drug discovery. Target-guided synthesis approaches including in situ click chemistry, by which reactive fragments are joined in the binding sites of a biological target, have shown great promise in drug discovery but have not been applied to GPCRs. The challenges lie in the GPCRs' membrane disposition, their high conformational dynamics, low stability and low expression levels. The proposed platform is being developed targeting all GPCRs, with initial focus primarily on those known to be cancer targets. In the two years of this study, we will focus on smoothened (SMO) receptor which is an orphan receptor and a key signal transducer in the Hedgehog (Hh) signaling pathway activated during development, and thus is a target of a number of antitumor drugs in clinical trials. Our goal will be attained by achieving the following two aims: (1) Establish an in situ click chemistry platform to generate high-affinity GPCR ligands, (2) Characterize the interaction between selected ligands from Aim 1 and SMO by crystallography. The study will be supported by a team that had developed the GPCR Structure Determination Pipeline as well as its underlying technologies which have led to the structure determination of 12 GPCR structures since 2007.